Christopher A Cottrell
Overview
Explore the profile of Christopher A Cottrell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
4642
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Romanov A, Knappe G, Ronsard L, Suh H, Omer M, Chapman A, et al.
bioRxiv
. 2025 Mar;
PMID: 40060683
Recruitment and expansion of rare precursor B cells in germinal centers (GCs) is a central goal of vaccination to generate broadly neutralizing antibodies (bnAbs) against challenging pathogens such as HIV....
2.
Ramezani-Rad P, Marina-Zarate E, Maiorino L, Myers A, Michaels K, Pires I, et al.
J Clin Invest
. 2025 Mar;
PMID: 40036068
The induction of durable protective immune responses is the main goal of prophylactic vaccines, and adjuvants play a role as drivers of such responses. Despite advances in vaccine strategies, a...
3.
Ramezani-Rad P, Cottrell C, Marina-Zarate E, Liguori A, Landais E, Torres J, et al.
bioRxiv
. 2025 Feb;
PMID: 39896562
A protective vaccine against HIV will likely need to induce broadly neutralizing antibodies (bnAbs) that engage relatively conserved epitopes on the HIV envelope glycoprotein (Env) trimer. Nearly all vaccine strategies...
4.
Peres A, Upadhyay A, Klein V, Klein V, Saha S, Rodriguez O, et al.
bioRxiv
. 2025 Jan;
PMID: 39829807
Rhesus macaques (RMs) are a vital model for studying human disease and invaluable to pre-clinical vaccine research, particularly for the study of broadly neutralizing antibody responses. Such studies require robust...
5.
Pratap P, Cottrell C, Quinn J, Carnathan D, Bader D, Tran A, et al.
bioRxiv
. 2024 Dec;
PMID: 39651156
During infection, the fusion peptide (FP) of HIV envelope glycoprotein (Env) serves a central role in viral fusion with the host cell. As such, the FP is highly conserved and...
6.
Ramezani-Rad P, Marina-Zarate E, Maiorino L, Myers A, Michaels K, Pires I, et al.
bioRxiv
. 2024 Aug;
PMID: 39211109
The induction of durable protective immune responses is the main goal of prophylactic vaccines, and adjuvants play an important role as drivers of such responses. Despite advances in vaccine strategies,...
7.
Cottrell C, Pratap P, Cirelli K, Carnathan D, Enemuo C, Antanasijevic A, et al.
NPJ Vaccines
. 2024 Jul;
9(1):126.
PMID: 38997302
Immunodominance of antibodies targeting non-neutralizing epitopes and the high level of somatic hypermutation within germinal centers (GCs) required for most HIV broadly neutralizing antibodies (bnAbs) are major impediments to the...
8.
Sharma V, Menis S, Brower E, Sayeed E, Ackland J, Lombardo A, et al.
Pharmaceutics
. 2024 Jun;
16(6).
PMID: 38931864
We describe the current Good Manufacturing Practice (cGMP) production and subsequent characterization of eOD-GT8 60mer, a glycosylated self-assembling nanoparticle HIV-1 vaccine candidate and germline targeting priming immunogen. Production was carried...
9.
Schiffner T, Phung I, Ray R, Irimia A, Tian M, Swanson O, et al.
Nat Immunol
. 2024 Jun;
25(7):1307.
PMID: 38877179
No abstract available.
10.
Schiffner T, Phung I, Ray R, Irimia A, Tian M, Swanson O, et al.
Nat Immunol
. 2024 May;
25(6):1073-1082.
PMID: 38816615
A key barrier to the development of vaccines that induce broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic diversity is the design of...